Australian Clinical Labs (ASX:ACL) - Aktienkurs, Nachrichten und Analyse

ACL Aktienübersicht

Australian Clinical Labs Limited erbringt pathologische Diagnosedienste in Australien. Mehr Details

ACL grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	3/6
Künftiges Wachstum	3/6
Vergangene Leistung	1/6
Finanzielle Gesundheit	4/6
Dividenden	2/6

Belohnungen

41.7% unter unserer Schätzung des beizulegenden Zeitwerts gehandelt

Prognostiziertes Gewinnwachstum 15.98% pro Jahr

Risikoanalyse

Große einmalige Posten, die sich auf die Finanzergebnisse auswirken

Die Dividende von 3.46% ist durch die Erträge nicht gut gedeckt

Die Gewinnspannen (3.4%) sind niedriger als im Vorjahr (5.2%)

Australian Clinical Labs Limited Wettbewerber

Healthia

ASX:HLA

AU$252.1m

SILK Laser Australia

ASX:SLA

AU$177.4m

Apiam Animal Health

ASX:AHX

AU$84.0m

Sonic Healthcare

ASX:SHL

AU$13.3b

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für Australian Clinical Labs
Historische Aktienkurse
Aktueller Aktienkurs	AU$3.47
52-Wochen-Hoch	AU$3.86
52-Wochen-Tief	AU$2.14
Beta	1.15
11 Monat Veränderung	-3.88%
3 Monate Veränderung	22.61%
1 Jahr Veränderung	35.55%
33 Jahre Veränderung	-17.97%
5 Jahre Veränderung	n/a
Veränderung seit IPO	1.46%

Aktuelle Nachrichten und Updates

Why Investors Shouldn't Be Surprised By Australian Clinical Labs Limited's (ASX:ACL) 29% Share Price Surge

Sep 03

Should You Think About Buying Australian Clinical Labs Limited (ASX:ACL) Now?

Sep 02

Recent updates

Why Investors Shouldn't Be Surprised By Australian Clinical Labs Limited's (ASX:ACL) 29% Share Price Surge

Sep 03

Here's Why We Think Australian Clinical Labs (ASX:ACL) Might Deserve Your Attention Today

Aug 14

Australian Clinical Labs Limited (ASX:ACL) Just Reported Half-Year Earnings: Have Analysts Changed Their Mind On The Stock?

Feb 25

New Forecasts: Here's What Analysts Think The Future Holds For Australian Clinical Labs Limited (ASX:ACL)

Dec 22

The Market Lifts Australian Clinical Labs Limited (ASX:ACL) Shares 31% But It Can Do More

Dec 21

The Strong Earnings Posted By Australian Clinical Labs (ASX:ACL) Are A Good Indication Of The Strength Of The Business

Sep 01

Aktionärsrenditen

	ACL	AU Healthcare	AU Markt
7D	-2.0%	0.7%	1.5%
1Y	35.5%	4.0%	17.2%

Rendite im Vergleich zur Industrie: ACL übertraf die Branche Australian Healthcare , die im vergangenen Jahr eine Rendite von 4 erzielte.

Rendite vs. Markt: ACL übertraf den Markt Australian, der im vergangenen Jahr eine Rendite von 17.2 erzielte.

Preisvolatilität

Is ACL's price volatile compared to industry and market?
ACL volatility
ACL Average Weekly Movement	5.0%
Healthcare Industry Average Movement	5.1%
Market Average Movement	8.6%
10% most volatile stocks in AU Market	17.3%
10% least volatile stocks in AU Market	3.4%

Stabiler Aktienkurs: ACL hat in den letzten 3 Monaten keine nennenswerten Preisschwankungen aufgewiesen.

Volatilität im Zeitverlauf: ACLDie wöchentliche Volatilität (5%) ist im vergangenen Jahr stabil geblieben.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
2020	4,900	Melinda McGrath	www.clinicallabs.com.au

Australian Clinical Labs Limited erbringt pathologische Diagnosedienste in Australien. Das Unternehmen bietet eine Reihe von Dienstleistungen, die Routine-Pathologie-Test, erweiterte molekulargenetische Tests, Harmonie NIPT und ersten Trimester-Screening, genetische Träger Screening, chemische Pathologie, Histopathologie und Zytopathologie, Hämatologie, Allergie und Immunologie, Serologie und Mikrobiologie, und infektiöse molekulare Tests, Herz-Test-Dienstleistungen, funktionelle Pathologie, Veterinär-Pathologie, und kommerzielle Drogen-und Alkohol-Test-Dienstleistungen umfassen. Das Unternehmen bietet seine Dienste privaten und öffentlichen Krankenhäusern an.

Australian Clinical Labs Limited's Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Australian Clinical Labs im Vergleich zum Marktanteil des Unternehmens?
ACL grundlegende Statistiken
Marktanteil	AU$682.41m
Gewinn(TTM)	AU$23.93m
Umsatz(TTM)	AU$696.37m

28.9x

Kurs-Gewinn-Verhältnis

1.0x

Kurs-Umsatz-Verhältnis

Ist ACL zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
ACL Gewinn- und Verlustrechnung (TTM)
Einnahmen	AU$696.37m
Kosten der Einnahmen	AU$442.37m
Bruttogewinn	AU$254.00m
Sonstige Ausgaben	AU$230.07m
Umsatz	AU$23.93m

Zuletzt gemeldete Gewinne

Jun 30, 2024

Datum des nächsten Gewinnberichts

Feb 26, 2025

Gewinn per Aktie (EPS)	0.12
Bruttomarge	36.48%
Nettogewinnspanne	3.44%
Schulden/Eigenkapital-Verhältnis	31.0%

Wie hat sich ACL auf lange Sicht entwickelt?

Historische Performance und Vergleiche

Dividenden

3.5%

Aktuelle Dividendenrendite

100%

Ausschüttungsquote

ACL Aktienübersicht

Belohnungen

Risikoanalyse

Australian Clinical Labs Limited Wettbewerber

ASX:HLA

AU$252.1m

ASX:SLA

AU$177.4m

ASX:AHX

AU$84.0m

ASX:SHL

AU$13.3b

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Australian Clinical Labs Limited to Report Fiscal Year 2025 Results on Aug 26, 2025

Investor sentiment improves as stock rises 25%

Why Investors Shouldn't Be Surprised By Australian Clinical Labs Limited's (ASX:ACL) 29% Share Price Surge

Should You Think About Buying Australian Clinical Labs Limited (ASX:ACL) Now?

Final dividend of AU$0.09 announced

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Recent updates

Australian Clinical Labs Limited to Report Fiscal Year 2025 Results on Aug 26, 2025

Investor sentiment improves as stock rises 25%

Why Investors Shouldn't Be Surprised By Australian Clinical Labs Limited's (ASX:ACL) 29% Share Price Surge

Should You Think About Buying Australian Clinical Labs Limited (ASX:ACL) Now?

Final dividend of AU$0.09 announced

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Australian Clinical Labs Limited Provides Financial Guidance for the Fiscal Year 2025

Australian Clinical Labs Limited to Report Fiscal Year 2024 Results on Aug 29, 2024

Australian Clinical Labs Limited, Annual General Meeting, Oct 25, 2024

We Think Australian Clinical Labs (ASX:ACL) Is Taking Some Risk With Its Debt

Upcoming dividend of AU$0.03 per share

Consensus EPS estimates fall by 20%

First half dividend reduced to AU$0.03

First half 2024 earnings released: EPS: AU$0.025 (vs AU$0.13 in 1H 2023)

Are Investors Undervaluing Australian Clinical Labs Limited (ASX:ACL) By 46%?

Australian Clinical Labs Limited to Report First Half, 2024 Results on Feb 28, 2024

Is It Time To Consider Buying Australian Clinical Labs Limited (ASX:ACL)?

Price target decreased by 7.5% to AU$3.56

Upcoming dividend of AU$0.07 per share at 4.6% yield

Consensus EPS estimates fall by 21%

Australian Clinical Labs Limited Announces Appointment of Christine Bartlett as Non-Executive Director

Australian Clinical Labs Limited Declares Full Year Fully Franked Dividend for the Fiscal Year 2023, Payable on 3 October 2023

Full year 2023 earnings: EPS and revenues miss analyst expectations

Upcoming dividend of AU$0.07 per share at 13% yield

Price target increased by 7.1% to AU$4.03

First half 2023 earnings released: EPS: AU$0.13 (vs AU$0.65 in 1H 2022)

Australian Clinical Labs Limited Announces Dividend for the Six Months Ended December 31, 2022, Payable on April 26, 2023

Investor sentiment improves as stock rises 16%

Price target decreased by 8.5% to AU$3.76

Price target decreased to AU$4.27

High number of new and inexperienced directors

Price target decreased to AU$4.62

Independent Non-Executive Director recently sold AU$71k worth of stock

Australian Clinical Labs Limited Announces Resignation of Dr. Michael Stanford as Non-Executive Director

Australian Clinical Labs Limited, Annual General Meeting, Oct 25, 2023

Independent Non-Executive Director recently sold AU$140k worth of stock

Upcoming dividend of AU$0.41 per share

Here's Why We Think Australian Clinical Labs (ASX:ACL) Might Deserve Your Attention Today

Full year 2022 earnings: EPS misses analyst expectations

Price target decreased to AU$5.30

Australian Clinical Labs Limited Declares Dividend for the Period of Six Months Ended 30 June 2022

Investor sentiment deteriorated over the past week

CEO & Executive Director recently bought AU$335k worth of stock

High number of new and inexperienced directors

First half 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Australian Clinical Labs Limited Declares Ordinary Dividend for the Period of Six Months December 31, 2021, Payable April 21, 2022

Australian Clinical Labs Limited (ASX:ACL) Just Reported Half-Year Earnings: Have Analysts Changed Their Mind On The Stock?

Australian Clinical Labs Limited Revises Earnings Guidance for the First Half 2022

New Forecasts: Here's What Analysts Think The Future Holds For Australian Clinical Labs Limited (ASX:ACL)

The Market Lifts Australian Clinical Labs Limited (ASX:ACL) Shares 31% But It Can Do More

Investor sentiment improved over the past week

Consensus EPS estimates increase by 46%

Australian Clinical Labs Limited (ASX:ACL) completed the acquisition of Medlab Pathology Pty Ltd.

Independent Non-Executive Director recently bought AU$99k worth of stock

The Strong Earnings Posted By Australian Clinical Labs (ASX:ACL) Are A Good Indication Of The Strength Of The Business

Full year 2021 earnings released: EPS AU$0.40 (vs AU$0.28 in FY 2020)

Australian Clinical Labs Limited Provides Earnings Guidance for the Fiscal Year of 2021

Australian Clinical Labs Limited has completed an IPO in the amount of AUD 408.559209 million.

Aktionärsrenditen

Erträge & Einnahmen